The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

The present invention relates to a novel dendrimer. The present invention also relates to formulations comprising the dendrimer with improved characteristics. For instance, the present invention relates to formulations comprising pesticides such as 2-(2,4-dichlorophenoxy)acetic acid with improved characteristics such as reduced crystallisation, compatibility with hard water and an extended shelf life at low temperatures.

The present invention relates to a novel dendrimer. The present invention also relates to formulations comprising the dendrimer with improved characteristics. For instance, the present invention relates to formulations comprising pesticides such as 2-(2,4-dichlorophenoxy)acetic acid with improved characteristics such as reduced crystallisation, compatibility with hard water and an extended shelf life at low temperatures.

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

Provided is a composition comprising a phenalkamine represented by formula (I), wherein, X is H or OH; R.sub.1 is an aliphatic chain with more than 8 carbon atoms, R.sub.2 is H, a C1-C10 alkyl, phenyl, or a C5-C6 cycloaliphatic group; R.sub.3 and R.sub.4 are independently CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2, or CH.sub.2CH.sub.2CH.sub.2CH.sub.2; and P and Q are, independent of each other, an integer. Also provided is a method for preparing the same.

##STR00001##

Provided is a composition comprising a phenalkamine represented by formula (I), wherein, X is H or OH; R.sub.1 is an aliphatic chain with more than 8 carbon atoms, R.sub.2 is H, a C1-C10 alkyl, phenyl, or a C5-C6 cycloaliphatic group; R.sub.3 and R.sub.4 are independently CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2, or CH.sub.2CH.sub.2CH.sub.2CH.sub.2; and P and Q are, independent of each other, an integer. Also provided is a method for preparing the same.

##STR00001##

The present invention relates to a preparation method for a tedizolid compound in Formula I. In Formula I, R is selected from hydrogen, formula A, formula B, benzyl or benzyl substituted by a substituent, the substituent is selected from a group consisting of halogen, nitryl, C.sub.1-C.sub.6 alkyl, and C.sub.1-C.sub.6 alkoxy, and R.sub.1 is C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 alkyl substituted by halogen. The method comprises: generating a compound having a structure as shown in Formula C and a compound having a structure as shown in Formula D by a coupled reaction under the catalysis of a metal catalyst, a substituent of R being defined as above, where X is a leaving group, the leaving group comprising chlorine, bromine, iodine, and sulfonyl oxy such as trifluoromethane sulfonic oxy, methylsulfonyl oxy and benzenesulfonyl oxy, or benzenesulfonyl oxy substituted by one or more substituents, the substituent being selected from a group consisting of halogen, C.sub.1-C.sub.6 alkyl, and C.sub.1-C.sub.6 alkoxy. ##STR00001##